Inspire Medical Systems, Inc. — 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. The filing also reports unaudited fourth-quarter results; this is an annual report, not a standalone quarterly filing.
Business context
Inspire develops and sells an implantable, closed-loop neurostimulation system for moderate-to-severe obstructive sleep apnea (OSA), primarily for U.S. patients unable to use or tolerate CPAP. The system is FDA-approved and sold directly to hospitals and ambulatory surgery centers in the U.S. and select European markets. Japan approved the therapy in June 2018; reimbursement there was still being pursued. The company reported more than 4,600 patients treated at over 245 medical centers across the U.S. and Europe.
Financial performance and liquidity
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Revenue | $50.6 million | $28.6 million |
| Gross profit / margin | $40.5 million / 80.1% | $22.5 million / 78.9% |
| Operating expenses | $60.9 million | $38.6 million |
| Operating loss | $20.4 million | $16.0 million |
| Net loss | $21.8 million | $17.5 million |
| Cash used in operating activities | $18.7 million | $15.8 million |
| Cash, cash equivalents and short-term investments at year-end | $188.2 million | $16.1 million |
| Credit-facility borrowings at year-end | $24.5 million | Not stated in this comparison table |
FY 2018 revenue grew 77.1%; U.S. revenue was $44.4 million, up 82.7%, and European revenue was $6.2 million, up 45.4%. The net loss widened as selling, general and administrative costs rose 65.4%, mainly with commercial-team growth, marketing and public-company costs. R&D expense increased 19.3%. Gross margin improved, partly because 2017 included a $0.5 million excess-inventory charge associated with the fourth-generation system. No income tax benefit was recorded, as deferred tax assets were fully offset by a valuation allowance.
Fourth-quarter 2018 revenue was $16.6 million versus $10.0 million in Q4 2017; gross profit was $13.4 million versus $8.1 million, and net loss was $4.8 million versus $4.3 million. Working capital at year-end was $188.1 million. The company raised approximately $112.0 million net in its May 2018 IPO and $69.8 million net in its December follow-on offering. It reported no remaining borrowing availability under its credit facility. Debt is secured by substantially all assets other than intellectual property; the interest-only period was extended to March 2020, with principal and interest then payable over 24 monthly installments and maturity in February 2022.
Material changes and operating developments
- Revenue increased from $28.6 million in 2017 to $50.6 million in 2018, while net loss increased from $17.5 million to $21.8 million.
- The U.S. share of revenue rose to 87.7% from 85.0%; Europe contributed 12.3% versus 15.0% in 2017.
- Positive coverage policies rose to 18 U.S. commercial payors, representing approximately 45 million covered lives. Aetna began coverage in July 2018. Approximately 60% of U.S. implants in 2018 received commercial prior authorization; Medicare accounted for approximately 30% and a federal veterans/military contract approximately 10%.
- The fourth-generation system was launched in Europe in 2018 after its U.S. launch in 2017. The FDA approved a redesigned sensing lead in January 2019, with U.S. introduction anticipated in March 2019. The company also reported a pending FDA application to expand the U.S. indication to patients as young as 12.
Outlook, commentary and key risks
Management expects continued revenue growth as awareness, sales capacity and reimbursement coverage expand, but cautions that results may fluctuate, including seasonally. It plans further investment in sales and marketing, R&D, clinical studies and international expansion. Management expects net losses for the next several years and substantial additional funding may be required; it stated existing cash resources were expected to fund operations for at least 12 months from the filing’s assessment.
Key risks include continued operating losses and cash burn; dependence on the Inspire system; limited and evolving commercial coverage and reimbursement; reliance on a small number of third-party and single-source suppliers; regulatory approval and post-market compliance requirements; product-liability and device-quality exposure; competition and adoption uncertainty; and execution of growth and international plans. Management disclosed no material legal proceedings and no off-balance-sheet arrangements. The company reported effective disclosure controls, but its auditor was not engaged to attest to internal control effectiveness under the applicable newly public-company transition relief.
Important facts for investors to verify
- Whether revenue growth and gross margin can be sustained as the company expands sales and patient access.
- How commercial coverage policies and prior-authorization success develop, and whether Medicare or other payors change their coverage.
- Operating cash burn, future financing needs and debt-service obligations, including the extended interest-only period and final payment fee.
- Whether supplier capacity, inventory levels and product launches can support growth without shortages or obsolescence charges.
- Progress on the pediatric indication, Japan reimbursement and other planned product or geographic expansion, alongside clinical and regulatory risks.